However, the secondary analysis appears biased. Of the 25 patients who were removed from the intention-to-treat closure group by the investigators to form the as-treated group, 4 (16%) had a stroke. Because this 16% stroke rate substantially exceeds the 3% background stroke rate among patients in the medical-therapy group, these 25 patients were not representative of the overall study population. Their underlying predisposition to stroke was clearly higher, and removing them from the analysis probably created an as-treated group at below-average risk.
In a press release, a representative of the device company notes the "compelling clinical benefits of closure." 1 The data do not provide support for his comments. Allan S. Brett, M.D.
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To the Editor: In the RESPECT trial, interventional and medical therapy yielded similar outcomes in patients with previous cryptogenic stroke and a patent foramen ovale. However, a subgroup analysis revealed better outcomes with percutaneous closure than medical therapy in patients with an atrial septal aneurysm or a moderate or severe right-to-left shunt. These results compare well with those of previous studies that show these anatomic conditions to be associated with a higher risk of recurrence of cerebrovascular events. 1, 2 The disparate findings between the general cohorts and subgroups suggest that patients were heterogeneous in terms of clinical risk; this resulted in an underpowered study, despite the larger number of patients enrolled relative to the PC Trial. Indeed, more generally, data are lacking from trials that enroll only patients with a high-risk patent foramen ovale. Nonetheless, risk assessment is only probabilistic in this condition. Therefore, while awaiting the results of conclusive trials, we recently published a position statement on the subject by eight national scientific societies. 3 This statement proposed that multidisciplinary teams of cardiologists, neurologists, and neuroradiologists (with additional input from hematologists) assign treatments on the basis of individual risk estimates according to clinical and anatomic factors (Fig. 1 CT denotes computed tomography, MRI magnetic resonance imaging, and PFO patent foramen ovale. Data are from Pristipino et al. 
To the Editor: The two recent trials of percutaneous closure of patent foramen ovale by Meier et al. and Carroll et al. leave unanswered questions. Mas et al. 1 provide useful guidance for future trial designs because they show that the combination of patent foramen ovale with an atrial septal aneurysm poses an elevated risk of stroke even when the patient receives aspirin. This highrisk combination clearly warrants consideration of either closure or anticoagulation, since antiplatelet therapy is ineffective. Aspirin alone appears to be effective for an isolated patent foramen ovale.
Many patients and clinicians who are faced with the choice of closure or anticoagulation would choose closure simply because of the unwanted risks and lifestyle modifications associated with anticoagulation, if the two methods were confirmed to be equally safe and efficacious. In this case, demonstration of the superiority of closure is unnecessary, since the decision by the patient and clinician would be served just as well by demonstration of noninferiority.
Thus, to show the noninferiority of closure as compared with anticoagulation and retain clinical equipoise, a useful trial design might be to include patients who have the combination of patent foramen ovale and an atrial septal aneurysm. To the Editor: The results of the RESPECT trial and the PC Trial showed no significant differences in outcomes between closure of the patent foramen ovale and medical therapy. The interventional community must be held responsible for the delayed enrollment, which began 10 years ago in the RESPECT trial and 13 years ago in the PC Trial. Concurrently, Swiss interventionalists, including Meier et al., reported a rate of closure of a patent foramen ovale that was 10 times as high as the total enrollment in the PC Trial; this highlights the enormous potential for device overuse even before evidence is available. 1 Although paradoxical embolism is rarely diagnosed during life, it is assumed to be a major cause of cryptogenic stroke in young patients. Yet, a patent foramen ovale is detected on transesophageal echocardiography in only about half these patients. Moreover, rates of stroke recurrence are low, and in the first randomized trial of closure of a patent foramen ovale, the causes of stroke recurrence were not related to a patent foramen ovale in 87% of the patients. Unfortunately, the PC Trial and RESPECT investigators did not report the cause of stroke recurrence; this precludes any clarification of who, if anyone, is likely to benefit from closure of a patent foramen ovale. Drs. Meier and Jüni Reply: Wood and Switchenko appropriately point out that both the PC Trial and the RESPECT trial were underpowered and that definite conclusions cannot be drawn. At the outset of the PC Trial, an annual event rate of at least 3% was assumed for patients in the medical-therapy group. As pointed out by MeyerCestone and Küchler, we estimate that only 5 to 10% of patients considered for closure of a patent foramen ovale were enrolled in the trial, and we assume that patients deemed to be at higher risk were directly referred for closure of a patent foramen ovale rather than being randomly assigned. Many investigators did not believe in equipoise of closure of a patent foramen ovale and medical therapy in these patients. This is likely to have resulted in low recruitment rates and considerably lower than expected event rates. Although chance is a plausible explanation for the observed results, the PC Trial and the RESPECT trial, taken together, suggest that a real benefit of closure of a patent foramen ovale with the PFO Occluder is an appreciably more likely explanation for observed results than chance alone.
We concur with Pristipino et al. that the characteristics of a patent foramen ovale affect the propensity of a patent foramen ovale to mediate paradoxical embolism. 1 However, the PC Trial and the RESPECT trial did not show a consistent outcome in subgroup analyses according to the severity of the shunt or the presence of an atrial septal aneurysm. Hence, we are uncertain about their recommendation that a low-risk patent foramen ovale should be treated by default with medical therapy after a first clinical event. The patient might have to be given a choice. Bern University Bern, Switzerland Since publication of their article, the authors report no further potential conflict of interest. Dr. Carroll and Colleagues Reply: Wood and Switchenko express concern about the low event rates seen in the RESPECT trial. A low risk of recurrence may be the true natural history of stroke related to patent foramen ovale. Followup from our study is ongoing. We agree that data are lacking from a meta-analysis of randomized trials, and we are collaborating in a pooled, patient-level analysis.
Brett raises the issue of bias in analyses involving different cohorts. We acknowledge that bias can occur even with prespecified analyses such as those in the RESPECT trial, but we submit that the totality of evidence must be presented and discussed. guide clinical practice when definitive evidence is lacking. We agree, 1 and we analyzed modifiers of the treatment effect with the use of a forest plot. A trial limited to patients with "high-risk patent foramen ovale" is problematic because it is not definitively known what features attributable to patent foramen ovale pose a high risk of recurrence. 2 We caution that the algorithm proposed in their figure is not based on randomized clinical trials but rather predominantly on clinical judgment, observational trials, and opinion as well as assumptions regarding pathophysiologic features. In our opinion, Newman's proposed noninferiority trial is not tenable, since anticoagulation has not been shown to be superior to antiplatelet therapy for a patent foramen ovale, with or without an atrial septal aneurysm.
Meyer-Cestone and Küchler bemoan the slow enrollment into the RESPECT trial and suggest that practice decisions are ahead of the data, especially when closure of the patent foramen ovale is the "genie out of the bottle." Incidental patent foramen ovale and recurrent strokes that are not related to patent foramen ovale complicate interpretation of trials. 2 We agree that the cause of stroke recurrence should be ascertained, with the caveat that assigning causation is not straightforward. 3 We recently presented data from RESPECT on mechanisms of recurrent stroke. 4 Finally, in their editorial, Messé and Kent note that clinical trials must guard against referral bias in adjudicating end points. The RESPECT trial used a validated questionnaire at every follow-up visit to identify symptoms of potential stroke or transient ischemic attack. 5 Any positive answer, no matter how trivial, triggered an automatic review of end points by an adjudication committee whose members were unaware of the treatment assignments. There were 232 referred events in the closure group and 244 referred events in the medical-therapy group. The high number of referrals (476 candidates with 25 confirmed events) and the balance of referrals across treatment groups confirm that referral bias was unlikely in the RESPECT trial. John D. Carroll, M.D.
Since publication of their article, the authors report no further potential conflict of interest. suggest that the detection of circulating tumor DNA in 58% of patients with metastatic breast cancer can be used as an effective indicator of tumor load during treatment with standard systemic therapies. The study does not address the clinical utility of circulating tumor DNA. Moreover, the authors claim that circulating tumor DNA represents a more effective monitoring tool than the enumeration of circulating tumor cells. This statement is incorrect, considering that the enumeration of circulating tumor cells proved the ability to predict prognosis and monitor treatment efficacy in all patients with metastatic breast cancer, regardless of disease subtype. 2 Furthermore, new detection methods describe the molecular heterogeneity and measure dynamic phenotypic changes in circulating tumor cells during metastasis. 3, 4 We propose that circulating tumor DNA provides a complementary method in the assessment of patients with detectable mutations and should be more appropriately used to select and monitor molecularly targeted therapies. Combined diagnostic methods will provide a more effective approach than each method alone to the implementation of precision medicine and improved clinical outcomes. Massimo Cristofanilli, M.D. Paolo Fortina, Ph.D.
